T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

Advances in hydrogel technology have unlocked unique and valuable capabilities that are
being applied to a diverse set of translational applications. Hydrogels perform functions …

The often immune-suppressive tumor microenvironment (TME) may hinder immune evasion
and response to checkpoint blockade therapies. Pharmacological activation of the STING …

Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

Virus-specific CD8+ T cells that differentiate in the context of resolved versus persisting
infections exhibit divergent phenotypic and functional characteristics, which suggests that …

Despite its remarkable clinical breakthroughs, immune checkpoint blockade (ICB) therapy
remains limited by the insufficient immune response in the “cold” tumor. Nanozyme‐based …

Abstract Anti–PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized
the treatment of many types of cancer over the past decade. The initial therapeutic …